Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T2FC
|
|||
| Former ID |
DNCL002101
|
|||
| Drug Name |
NPC-1C
|
|||
| Synonyms |
Ensituximab
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 2 | [1] | |
| Pancreatic cancer [ICD-11: 2C10] | Phase 2 | [2] | ||
| Pancreatic tumour [ICD-11: 2C10; ICD-9: 157] | Phase 2 | [3] | ||
| Company |
Neogenix Oncology
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neoplasm antigen (NA) | Target Info | . | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031614) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | National Cancer Institute Drug Dictionary (drug id 663436). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.